A phase I trial of ALKS-4510
Latest Information Update: 25 Feb 2025
At a glance
- Drugs ALKS 4510 (Primary)
- Indications CNS disorders
- Focus Adverse reactions
Most Recent Events
- 25 Feb 2025 New trial record
- 12 Feb 2025 According to an Alkermes plc media release, the company expect to start phase I trial in second half of 2025.